Correction: Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease

Ítems similars

• Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
  per: Ray, Balmiki, et al.
  Publicat: (2020)
• Rivastigmine Lowers Aβ and Increases sAPPα Levels, Which Parallel Elevated Synaptic Markers and Metabolic Activity in Degenerating Primary Rat Neurons
  per: Bailey, Jason A., et al.
  Publicat: (2011)
• Are pulmonary fibrosis and Alzheimer's disease linked? Shared dysregulation of two miRNA species and downstream pathways accompany both disorders
  per: Lahiri, Debomoy K., et al.
  Publicat: (2017)
• Memantine treatment decreases levels of secreted Alzheimer’s amyloid precursor protein (APP) and amyloid beta (Aβ) peptide in the human neuroblastoma cells
  per: Ray, Balmiki, et al.
  Publicat: (2009)
• Finding novel distinctions between the sAPPα-mediated anabolic biochemical pathways in Autism Spectrum Disorder and Fragile X Syndrome plasma and brain tissue
  per: Ray, Balmiki, et al.
  Publicat: (2016)